1. Home
  2. News

News

Milestone 1000 patients in trials Anticancer Fund

More than 1.000 patients participating in Anticancer Fund clinical trials

On International Clinical Trials Day, we’ve reached a milestone: more than 1.000 patients are participating in our 7 ongoing clinical trials across 31 countries. These numbers represent more than data — they represent progress, and lives. Discover how smart research is driving change.

Brain tumour in children - U-R-Immune Glioma trial by Anticancer Fund

New clinical trial targets aggressive brain tumours in children and young adults

We started a global trial, U-R-Immune Glioma, investigating whether Immune therapy can offer an alternative treatment for children and young adults with brain tumours. In collaboration with SickKids and CHEO in Canada.

ReDO: cimetidine as an anti-cancer agent

Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., & Sukhatme, V. P. (2014). Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent. Ecancermedicalscience, 8, 485. doi:10.3332/ecancer.2014.485

Inconsistencies and questionable reliability of Yamamoto's publication on GcMAF

Ugarte, A., Bouche, G., & Meheus, L. (2014). Inconsistencies and questionable reliability of the publication "immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF" by Yamamoto et al. Cancer Immunology Immunotherapy, 63(12), 1347-8. doi: 10.1007/s00262-014-1587-y

Repurposing Drugs in Oncology (ReDO) Project

Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., & Sukhatme, V. P. (2014). The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience, 8, 442. doi:10.3332/ecancer.2014.442

ReDO: mebendazole as an anti-cancer agent

Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., & Sukhatme, V. P. (2014). Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent. Ecancermedicalscience, 8, 443. doi:10.3332/ecancer.2014.443